Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02775981 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function
A Phase 1 study, sponsored by Pharmaceutical Project Solutions.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02775981: Completed Phase 1 study, sponsored by Pharmaceutical Project Solutions.
NCT02775981 is a Phase 1 study that has completed, run by Pharmaceutical Project Solutions. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02775981, a Phase 1 study, has completed, sponsored by Pharmaceutical Project Solutions.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the potential effect of hepatic impairment on the systemic pharmacokinetics of RX0041-002 following single dose intranasal administration. The secondary objective is to evaluate the safety and tolerability of intranasal RX0041-002 in subjects with normal hepatic function and hepatic impairment.
Interventions
- DRUG RX0041-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
What the finished NCT02775981 record still lists
NCT02775981 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 1 intervention - of which RX0041-002 is the first listed.
NCT02775981 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02775981 about?
NCT02775981 is a clinical study titled "Pharmacokinetic Study of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function". The primary objective of this study is to evaluate the potential effect of hepatic impairment on the systemic pharmacokinetics of RX0041-002 following single dose intranasal administration. The secondary objective is to evaluate the safety and tolerability of intranasal RX0041-002 in subjects with n...
What is the current status of trial NCT02775981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-02. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02775981?
The interventions under investigation include: RX0041-002 (DRUG).
Who is sponsoring clinical trial NCT02775981?
This trial is sponsored by Pharmaceutical Project Solutions, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02775981's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia